PT97660A - Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina - Google Patents

Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina

Info

Publication number
PT97660A
PT97660A PT97660A PT9766091A PT97660A PT 97660 A PT97660 A PT 97660A PT 97660 A PT97660 A PT 97660A PT 9766091 A PT9766091 A PT 9766091A PT 97660 A PT97660 A PT 97660A
Authority
PT
Portugal
Prior art keywords
inhibitor
hypocolesterolizing
angiotensin
conversation
enzyme
Prior art date
Application number
PT97660A
Other languages
English (en)
Other versions
PT97660B (pt
Inventor
James L Bergey
Werner Tschollar
Cary S Yonce
James C Kawano
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of PT97660A publication Critical patent/PT97660A/pt
Publication of PT97660B publication Critical patent/PT97660B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97660A 1990-05-15 1991-05-14 Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina PT97660B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52426690A 1990-05-15 1990-05-15

Publications (2)

Publication Number Publication Date
PT97660A true PT97660A (pt) 1992-02-28
PT97660B PT97660B (pt) 1998-09-30

Family

ID=24088484

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97660A PT97660B (pt) 1990-05-15 1991-05-14 Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina

Country Status (15)

Country Link
EP (1) EP0457514B1 (pt)
JP (1) JPH04226921A (pt)
KR (1) KR100200467B1 (pt)
AT (1) ATE141514T1 (pt)
AU (1) AU651579B2 (pt)
CA (1) CA2040865C (pt)
DE (1) DE69121464T2 (pt)
DK (1) DK0457514T3 (pt)
ES (1) ES2090244T3 (pt)
GR (1) GR3021703T3 (pt)
HU (1) HU212102B (pt)
IE (1) IE77637B1 (pt)
NZ (1) NZ237929A (pt)
PT (1) PT97660B (pt)
ZA (1) ZA913509B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
AU3473193A (en) * 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
DE4402379C2 (de) * 1994-01-27 1997-09-25 Lohmann Therapie Syst Lts Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
SI1009400T1 (en) 1997-08-29 2005-04-30 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6172441B1 (en) 1999-06-28 2001-01-09 Visteon Global Technologies, Inc. Rotor assembly
PL353199A1 (en) 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20040137054A1 (en) * 2002-05-03 2004-07-15 Alexandra Hager Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004085448A2 (en) * 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
CN1903364B (zh) * 2005-07-26 2011-06-22 安徽省现代中药研究中心 含有血管紧张素转化酶抑制剂和苯氧酸类化合物的药物组合物
JP2012510511A (ja) * 2008-12-01 2012-05-10 インヴアスク セラピューテイックス インコーポレイテッド レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3536687A1 (de) * 1985-10-15 1987-04-16 Hoechst Ag Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit

Also Published As

Publication number Publication date
KR100200467B1 (ko) 1999-06-15
ES2090244T3 (es) 1996-10-16
IE911431A1 (en) 1991-11-20
HUT57993A (en) 1992-01-28
CA2040865C (en) 2002-07-23
IE77637B1 (en) 1997-12-31
DE69121464T2 (de) 1997-03-27
AU7627091A (en) 1991-11-21
NZ237929A (en) 1997-06-24
DK0457514T3 (da) 1996-09-16
GR3021703T3 (en) 1997-02-28
PT97660B (pt) 1998-09-30
DE69121464D1 (de) 1996-09-26
KR910019614A (ko) 1991-12-19
EP0457514A1 (en) 1991-11-21
EP0457514B1 (en) 1996-08-21
ZA913509B (en) 1992-02-26
CA2040865A1 (en) 1991-11-16
HU911620D0 (en) 1991-11-28
HU212102B (en) 1996-02-28
AU651579B2 (en) 1994-07-28
ATE141514T1 (de) 1996-09-15
JPH04226921A (ja) 1992-08-17

Similar Documents

Publication Publication Date Title
PT97660A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um agente hipocolesterolizante e um inibidor da enzima de conversao da angiotensina
BR0013704A (pt) Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
MX9702175A (es) Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
TR200101867T2 (tr) CCR5 modülatörleri olarak piperidinler
BR9908690A (pt) Composição farmacêutica contendo estatina e aspirina
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
DK0738512T3 (da) Fremgangsmåde til forebyggelse af et andet hjerteanfald ved anvendelse af en HMG coenzsym A reduktasehæmmer
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
BR9914044A (pt) ésteres tetrahidropirido
IL141786A0 (en) A pharmaceutical composition for treating diabetes containing an ap2 inhibitor
CA2289717A1 (en) Novel therapy for constipation
BR9503406A (pt) Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
AU689817B2 (en) Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
BR9708864A (pt) Composto composição farmacêutica e processo para o tratamento ou a prevenção de uma infecção bacteriana em um paciente mamífero
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
NZ505637A (en) E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol and pharmaceutical compositions useful in lowering serum cholesterol
AU2961199A (en) Hiv cofactor inhibitors and medicinal compositions for preventing or treating hiv-infection
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
ES2192018T3 (es) Composicion farmaceutica que contiene estimuladores de interferon-gamma.
BR9813634A (pt) "abridores de canal de potássio"

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19911028

FG3A Patent granted, date of granting

Effective date: 19980602

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130603